AMIKIN 250 MG — DIN 00397415
AMIKACIN (AMIKACIN SULFATE) : 250 MG · BRISTOL-MYERS SQUIBB CANADA · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is AMIKIN?
AMIKIN 250 MG contains AMIKACIN (AMIKACIN SULFATE) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00397415, held by BRISTOL-MYERS SQUIBB CANADA, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 29-May-2006. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is AMIKIN used for?
Short term treatment of serious infections due to susceptible strains of Gram-negative organisms and Staphylococcus aureus, including septicemia, respiratory, urinary tract, and intra-abdominal.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Amikacin cost around the world?
Amikacin is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 22 | 22 | EUR███.██ |
| Saudi Arabia | public | 11 | 12 | SAR███.██ |
| South Africa | single exit price | 8 | 10 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 4 | 7 | CZK███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
60 pack listings across 54 brand entries and 9 price bases, refreshed 05 Sep 2026. Ranges span every Amikacin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Amikacin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Amikacin, across 9 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 1 | 1 | AMIKACIN SULFATE INJECTION | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | AMIKACIN SULFATE INJECTION USP | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 1 | 1 | AMIKACIN SULFATE INJECTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | AMIKACIN SULFATE INJECTION USP | Sourceable in Canada |
| BRISTOL-MYERS SQUIBB CANADA | 1 | 0 | AMIKIN | No marketed DIN |
| HIKMA CANADA LIMITED | 1 | 0 | AMIKACIN SULFATE INJECTION | No marketed DIN |
| JUNO PHARMACEUTICALS CORP. | 1 | 0 | AMIKACIN SULFATE INJECTION | No marketed DIN |
| SEARCHLIGHT PHARMA INC | 1 | 0 | ERFA-AMIKACIN | No marketed DIN |
| VPI PHARMACEUTICALS INC | 1 | 0 | VPI-AMIKACIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
| Pack configuration (monograph) | Single dose vials of 500 mg in 2 mL volume (250 mg/mL). |
| Storage | Store at room temperature (requires no refrigeration). Solutions for IV administration should be used within 12 hours after preparation. Discard dark coloured solutions. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Amikacin |
|---|---|
| ATC code | J01GB06 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00397415 |
|---|---|
| DIN (unpadded, as printed on some documents) | 397415 |
| Brand name | AMIKIN |
| Generic / active ingredient | AMIKACIN (AMIKACIN SULFATE) : 250 MG |
| Market authorization holder | BRISTOL-MYERS SQUIBB CANADA |
| Health Canada schedule | Prescription |
| ATC code | J01GB06 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01GB |
| Current status | CANCELLED POST MARKET |
| Status date | 29-May-2006 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults/Children/Neonates: 15 mg/kg/day (7.5 mg/kg every 12 hours) IM or IV. Max adult dose 15 g per course; max 1.5 g/day. Treatment usually 7-10 days. Adjust interval in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known allergy to amikacin or any component of the formulation; history of hypersensitivity or serious toxic reactions to aminoglycosides due to known cross-sensitivities.
Warnings and precautions
Potential for irreversible ototoxicity (auditory and vestibular) and nephrotoxicity. Risk increases with impaired renal function, high doses, or prolonged therapy (>14 days).
Is Amikacin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by OMEGA LABORATORIES LIMITED, last seen 12 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02529459 |
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02486717 |
| AMIKACIN SULFATE INJECTION USP | 500 MG / 2 ML | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02481073 |
| AMIKACIN SULFATE INJECTION USP | 250 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | 02242971 |
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | CANCELLED PRE MARKET | 02539535 |
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | HIKMA CANADA LIMITED | CANCELLED POST MARKET | 02525909 |
| ERFA-AMIKACIN | 250 MG | SOLUTION | SEARCHLIGHT PHARMA INC | CANCELLED POST MARKET | 02489147 |
| VPI-AMIKACIN | 500 MG / 2 ML | SOLUTION | VPI PHARMACEUTICALS INC | DORMANT | 02506599 |
2 · Same class — other molecules in ATC J01GB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tobramycin | AJ-TOBRAMYCIN · JAMP-TOBRAMYCIN · NEBCIN INJ 1.2GM/30ML · NEBCIN INJ 10MG/ML · +14 more | 23 | 9 | Yes |
| Gentamicin | CIDOMYCIN INJ 10MG/ML · CIDOMYCIN INJ 40MG/ML · CIDOMYCIN INJ PEDIATRIC 10MG · GARAMYCIN INJ 10MG/ML PEDIATRIC · +10 more | 20 | 6 | Yes |
| Amikacin | AMIKACIN SULFATE INJECTION · AMIKACIN SULFATE INJECTION USP · AMIKIN · ERFA-AMIKACIN · +1 more | 9 | 4 | Yes |
| Neomycin | MYCIFRADIN SULFATE ORAL SOLUTION · MYCIFRADIN SULFATE TABLETS 0.5 GM | 2 | 0 | Not in Canada |
| Netilmicin | NETROMYCIN INJ 100MG/ML · NETROMYCIN INJ 50MG/ML | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01G
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01GA | Streptomycin | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is AMIKIN called?
The same molecule, Amikacin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Amikacin | Latin | Iceland, Saudi Arabia |
| AMIKACIN B. BRAUN | Latin | Czechia |
| AMIKACIN FRESENIUS KABI | Latin | Czechia |
| AMIKACIN OLIKLA | Latin | Czechia |
| AMIKACIN MEDOCHEMIE | Latin | Czechia |
| AMIKACIN SULPHATE | Latin | Lebanon |
| AMKANT | Latin | Saudi Arabia |
| ARIKAYCE | Latin | Saudi Arabia |
| Arikayce liposomal | Latin | Iceland |
| SELEMYCIN | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.